NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00009-0287-01 | 00009-0287 | medroxyprogesterone acetate | Provera | 5.0 mg/1 | Hormonal Therapy | Progestin | Oral | Nov. 11, 2018 | In Use | ||
74527-0022-02 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan. 15, 2021 | In Use | |
74527-0022-03 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan. 15, 2021 | In Use | |
79952-0110-01 | 79952-0110 | loncastuximab tesirine | ZYNLONTA | 10.0 mg/2mL | Immunotherapy | Drug Antibody Conjugate | CD19 | Intravenous | April 30, 2021 | In Use | |
68152-0112-01 | 68152-0112 | levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan. 2, 2019 | In Use | |
68152-0114-01 | 68152-0114 | levoleucovorin | KHAPZORY | 300.0 mg/6mL | Ancillary Therapy | Antiemetic | Antidote | Intravenous | Jan. 2, 2019 | In Use | |
00078-0916-61 | 00078-0916 | letrozole and ribociclib | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
00078-0923-61 | 00078-0923 | letrozole and ribociclib | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
70518-1869-00 | 70518-1869 | letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 13, 2019 | Sept. 23, 2019 | No Longer Used | |
68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sept. 29, 2020 | In Use |
Found 10,000 results in 4 milliseconds — Export these results